V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240001113 | 240001113 | 1.66 | 80 | Disease modification (D) | null | 2019-10-21 | AML16 DA 3+10 | 1 | N | CYTARABINE + DAUNORUBICIN | 100108848 |
| 240001114 | 240001114 | 1.79 | null | Curative (C) | null | 2019-01-31 | Alemtuzumab cond (RI ALLO CAMP100) | 02 | N | DA | 101336567 |
| 240001120 | 240001120 | null | 71.95 | null | 2018-07-26 | 2018-07-26 | FLAIR trial | N | N | HYDROXYCARBAMIDE | 101744835 |
| 240001124 | 240001124 | 1.61 | 96.7 | Curative (C) | null | 2016-01-28 | null | 02 | Y | CHLORAMBUCIL + OBINUTUZUMAB | 100381244 |
| 240001125 | 240001125 | 1.5 | 25.7 | Neo-adjuvant (N) | null | 2018-04-17 | CYTARABINE + DAUNORUBICIN | null | N | IMATINIB | 101386883 |
| 240001126 | 240001126 | 1.77 | 68 | Curative (C) | null | 2019-12-14 | FCR | 02 | N | CYTARABINE + DAUNORUBICIN | 100907568 |
| 240001134 | 240001134 | 1.72 | 62 | Curative (C) | null | 2015-11-27 | Rituximab | 02 | null | AML19 TRIAL | 100792758 |
| 240001150 | 240001150 | 1.78 | 73.5 | Curative (C) | 2019-10-21 | 2019-10-21 | null | null | N | GEMTUZUMAB OZOGAMICIN | 101047537 |
| 240001151 | 240001151 | 1.57 | 89.6 | Curative (C) | 2015-02-13 | 2015-02-14 | null | 02 | N | DA | 100460699 |
| 240001161 | 240001161 | 1.68 | 88.55 | Palliative (P) | null | 2017-02-14 | Bortezomib + CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB | 1 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101087768 |
| 240001163 | 240001163 | 1.72 | 100 | 03 | null | 2016-04-22 | null | 02 | N | CYTARABINE HIGH DOSE | 100416222 |
| 240001167 | 240001167 | 1.72 | 63.5 | Curative (C) | null | 2016-06-24 | null | 02 | N | IBRUTINIB | 101752899 |
| 240001172 | 240001172 | 1.46 | 66.3 | Palliative (P) | null | 2015-11-25 | null | 02 | N | CHOP R | 100347659 |
| 240001174 | 240001174 | 1.66 | 72.2 | Curative (C) | null | 2018-06-16 | DA | 02 | N | AZACITIDINE | 100027623 |
| 240001182 | 240001182 | 1.67 | null | Disease modification (D) | null | 2019-09-24 | CHOEP - 21 days | 02 | N | CYTARABINE + DAUNORUBICIN + GEMTUZUMAB OZOGAMICIN | 100095083 |
| 240001184 | 240001184 | 1.73 | 84 | 03 | null | 2019-09-20 | null | 02 | N | AML19 TRIAL | 100758459 |
| 240001186 | 240001186 | 1.72 | 65 | Curative (C) | 2016-04-01 | 2016-04-02 | Methotrexate intrathecal | 02 | N | CHOP R | 101047071 |
| 240001193 | 240001193 | null | null | null | null | 2019-02-26 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101633563 |
| 240001196 | 240001196 | 1.67 | 61.1 | 03 | null | 2016-08-23 | CYTARABINE + DAUNORUBICIN | N | N | LIPOSOMAL DAUNORUBICIN + LIPOSOMAL CYTARABINE (VYXEOS) | 101319553 |
| 240001199 | 240001199 | 1.72 | 20 | Curative (C) | null | 2017-08-21 | ALL Interim Guide 2019 Induction B | 2 | N | CYTARABINE | 100674767 |
| 240001200 | 240001200 | null | null | null | null | 2018-02-08 | Hydroxycarbamide | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100364062 |
| 240001201 | 240001201 | null | null | null | null | 2018-02-11 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | null | null | AML16 TRIAL | 101635703 |
| 240001202 | 240001202 | 0 | 67 | Disease modification (D) | null | 2019-05-31 | DA | N | N | AML18 TRIAL | 100267596 |
| 240001215 | 240001215 | 1.57 | 94.8 | Curative (C) | 2018-11-15 | 2018-11-16 | null | 02 | N | CHOP | 100529520 |
| 240001218 | 240001218 | 1.67 | 44.45 | Curative (C) | 2016-02-09 | 2016-02-10 | Bortezomib + Thalidomide +/- Dex | 02 | N | TRIAL | 100712909 |
| 240001224 | 240001224 | 1.85 | 64.4 | Curative (C) | 2017-09-08 | 2017-09-08 | FCR Oral - Cycle 1 | 02 | N | HYDROXYCARBAMIDE | 101565579 |
| 240001230 | 240001230 | null | null | null | null | 2017-10-25 | AML 18 TRIAL | null | null | DA | 101579153 |
| 240001231 | 240001231 | 1.72 | null | Curative (C) | null | 2016-01-20 | CHOP R - 21 days | N | N | AZACITIDINE | 100847367 |
| 240001239 | 240001239 | 1.53 | 84 | Adjuvant (A) | null | 2017-11-22 | null | 02 | N | BORTEZOMIB + THALIDOMIDE | 100419587 |
| 240001263 | 240001263 | 1.67 | 64 | Curative (C) | null | 2019-02-13 | null | 02 | N | NOT MATCHED | 100162072 |
| 240001267 | 240001267 | null | null | null | null | 2016-07-13 | null | null | null | BENDAMUSTINE + RITUXIMAB | 101063164 |
| 240001274 | 240001274 | null | null | null | null | 2018-10-25 | null | null | null | AML19 TRIAL | 100221957 |
| 240001276 | 240001276 | null | 104 | Curative (C) | null | 2017-12-14 | Rituximab | N | Y | BORTEZOMIB | 101172836 |
| 240001283 | 240001283 | 1.68 | 0 | Palliative (P) | 2017-06-19 | 2017-06-20 | Trial Unspecified | 02 | N | RITUXIMAB | 100741429 |
| 240001285 | 240001285 | 1.74 | 62.6 | Curative (C) | null | 2017-11-11 | null | 02 | N | ARSENIC TRIOXIDE + TRETINOIN | 100645023 |
| 240001286 | 240001286 | 1.81 | 61.3 | Curative (C) | null | 2016-07-14 | Hydroxycarbamide | 01 | N | AZACITIDINE | 101086092 |
| 240001290 | 240001290 | 1.75 | 64.25 | Adjuvant (A) | null | 2019-12-14 | CHOP R | N | N | CYTARABINE | 100370457 |
| 240001293 | 240001293 | null | null | null | null | 2016-03-06 | null | null | null | IMATINIB | 101561451 |
| 240001298 | 240001298 | null | null | null | null | 2017-01-24 | null | null | null | FCR | 100196729 |
| 240001310 | 240001310 | null | null | null | null | 2018-08-26 | null | null | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101573523 |
| 240001313 | 240001313 | null | null | null | null | 2018-10-29 | null | null | null | CHOP R | 101655560 |
| 240001321 | 240001321 | 1.95 | 56.7 | Curative (C) | null | 2017-08-30 | DA 3 + 10 | N | N | TRIPLE INTRATHECAL | 100242044 |
| 240001323 | 240001323 | null | null | null | null | 2018-10-09 | Arsenic Triox + Tretinoin Ind W1-4 | null | null | AML18 TRIAL | 100827949 |
| 240001324 | 240001324 | 1.59 | 96 | Curative (C) | 2018-05-09 | 2018-05-09 | AML 19 TRIAL | N | N | CYTARABINE + DAUNORUBICIN | 100378622 |
| 240001331 | 240001331 | 1.7 | 34.6 | Curative (C) | 2016-07-21 | 2016-07-25 | PACLITAXEL | 2 | N | CHOP R | 100690189 |
| 240001338 | 240001338 | 1.74 | null | Adjuvant (A) | null | 2017-12-28 | Hydroxycarbamide | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 100723064 |
| 240001343 | 240001343 | null | null | 03 | null | 2018-02-02 | AML16 DA 3+10 | 02 | N | CLADRIBINE + RITUXIMAB | 101720674 |
| 240001347 | 240001347 | null | null | null | null | 2018-04-30 | CHOP R - 21 days | null | null | AML19 TRIAL | 101661093 |
| 240001349 | 240001349 | 1.65 | 102.6 | Curative (C) | 2017-11-17 | 2017-11-26 | null | 02 | N | IMATINIB | 101393881 |
| 240001352 | 240001352 | 0 | 49.3 | 03 | null | 2018-03-19 | AML 18 TRIAL | 02 | N | AML19 TRIAL | 100361797 |